Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPT-LAA: Single antiplatelet vs reduced-dose anticoagulant strategies after WATCHMAN FLX Pro LAA closure
jRCTs031240174Active, not recruiting
- Sponsor
- Chiba University Graduate School of Medicine Department of Advanced Arrhythmia Bioengineering
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of aspirin, Draxaban, clopidogrel and prasugrel in Atrial fibrillation (AFib), stroke and systemic embolism (2 arms), sponsored by Chiba University Graduate School of Medicine Department of Advanced Arrhythmia Bioengineering. Primary endpoint: Primary composite endpoint at 6 months. Started Jul 2024; status: active, not recruiting.
02
Drugs
aspirinDraxabanclopidogrelprasugrel
03
Conditions
Atrial fibrillation (AFib)strokesystemic embolism
Beyond the preview
Go deeper on jRCTs031240174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240174.